E Wilson Grandin1,2, Gaurav Gulati3, Jose I Nunez1, Kevin Kennedy2, J Eduardo Rame4, Pavan Atluri5, Francis D Pagani6, James K Kirklin7, Robert L Kormos8,9, Jeffrey Teuteberg10, Michael S Kiernan3. 1. Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston MA (E.W.G., J.I.N.). 2. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (E.W.G., K.K.). 3. Cardiovascular Center, Tufts Medical Center, Boston, MA (G.G., M.S.K.). 4. Division of Cardiology, Jefferson Heart Institute, Philadelphia, PA (J.E.R.). 5. Division of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia (P.A.). 6. Division of Cardiothoracic Surgery, University of Michigan School of Medicine, Ann Arbor (F.D.P.). 7. Division of Cardiothoracic Surgery, University of Alabama Birmingham School of Medicine (J.K.K.). 8. Division of Cardiothoracic Surgery, University of Pittsburgh, PA (R.L.K.). 9. Abbott Laboratories, Austin, TX (R.L.K.). 10. Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, CA (J.T.).
Abstract
BACKGROUND: Elevated right ventricular afterload following continuous-flow left ventricular assist device (CF-LVAD) may contribute to late right heart failure (LRHF). PDE5i (phosphodiesterase-5 inhibitors) are used to treat pulmonary hypertension and right heart dysfunction after CF-LVAD, but their impact on outcomes is uncertain. METHODS: We queried Interagency Registry for Mechanically Assisted Circulatory Support from 2012 to 2017 for adults receiving a primary CF-LVAD and surviving ≥30 days from index discharge. Patients receiving early PDE5i (ePDE5i) at 1 month were propensity-matched 1:1 with controls. The primary outcome was the cumulative incidence of LRHF, defined using prevailing Interagency Registry for Mechanically Assisted Circulatory Support criteria; secondary outcomes included all-cause mortality and major bleeding. RESULTS: Among 9627 CF-LVAD recipients analyzed, 2463 (25.6%) received ePDE5i and 1600 were propensity-matched 1:1 with controls. Before implant, ePDE5i patients had more severe RV dysfunction (13.1% versus 9.6%) and higher pulmonary vascular resistance (2.8±2.7 versus 2.2±2.4 WU), both P<0.001, but clinical factors were well-balanced after propensity-matching. In the unmatched cohort, ePDE5i patients had a higher 3-year cumulative incidence of LRHF, mortality, and major bleeding, but these differences were attenuated in the propensity-matched cohort: LRHF 40.8% versus 35.7% (hazard ratio, 1.14 [95% CI, 0.99-1.32]; P=0.07); mortality 38.6% versus 35.8% (hazard ratio, 0.99 [95% CI, 0.86-1.15]; P=0.93); major bleeding 51.2% versus 46.0% (hazard ratio, 1.12 [95% CI, 0.99-1.27]; P=0.06). CONCLUSIONS: Compared with propensity-matched controls, adult CF-LVAD patients receiving ePDE5i had similar rates of LRHF, mortality, and major bleeding. While intrinsic patient risk factors likely account for more adverse outcomes with ePDE5i in the unmatched cohort, there is no obvious benefit of ePDE5i in the LVAD population.
BACKGROUND: Elevated right ventricular afterload following continuous-flow left ventricular assist device (CF-LVAD) may contribute to late right heart failure (LRHF). PDE5i (phosphodiesterase-5 inhibitors) are used to treat pulmonary hypertension and right heart dysfunction after CF-LVAD, but their impact on outcomes is uncertain. METHODS: We queried Interagency Registry for Mechanically Assisted Circulatory Support from 2012 to 2017 for adults receiving a primary CF-LVAD and surviving ≥30 days from index discharge. Patients receiving early PDE5i (ePDE5i) at 1 month were propensity-matched 1:1 with controls. The primary outcome was the cumulative incidence of LRHF, defined using prevailing Interagency Registry for Mechanically Assisted Circulatory Support criteria; secondary outcomes included all-cause mortality and major bleeding. RESULTS: Among 9627 CF-LVAD recipients analyzed, 2463 (25.6%) received ePDE5i and 1600 were propensity-matched 1:1 with controls. Before implant, ePDE5i patients had more severe RV dysfunction (13.1% versus 9.6%) and higher pulmonary vascular resistance (2.8±2.7 versus 2.2±2.4 WU), both P<0.001, but clinical factors were well-balanced after propensity-matching. In the unmatched cohort, ePDE5i patients had a higher 3-year cumulative incidence of LRHF, mortality, and major bleeding, but these differences were attenuated in the propensity-matched cohort: LRHF 40.8% versus 35.7% (hazard ratio, 1.14 [95% CI, 0.99-1.32]; P=0.07); mortality 38.6% versus 35.8% (hazard ratio, 0.99 [95% CI, 0.86-1.15]; P=0.93); major bleeding 51.2% versus 46.0% (hazard ratio, 1.12 [95% CI, 0.99-1.27]; P=0.06). CONCLUSIONS: Compared with propensity-matched controls, adult CF-LVAD patients receiving ePDE5i had similar rates of LRHF, mortality, and major bleeding. While intrinsic patient risk factors likely account for more adverse outcomes with ePDE5i in the unmatched cohort, there is no obvious benefit of ePDE5i in the LVAD population.
Authors: Brian A Houston; Rohan J Kalathiya; Gerin R Stevens; Stuart D Russell; Ryan J Tedford Journal: J Heart Lung Transplant Date: 2015-07-29 Impact factor: 10.247
Authors: Barry A Borlaug; Gregory D Lewis; Steven E McNulty; Marc J Semigran; Martin LeWinter; Horng Chen; Grace Lin; Anita Deswal; Kenneth B Margulies; Margaret M Redfield Journal: Circ Heart Fail Date: 2015-03-17 Impact factor: 8.790
Authors: Barry A Borlaug; Vojtech Melenovsky; Tricia Marhin; Patricia Fitzgerald; David A Kass Journal: Circulation Date: 2005-10-25 Impact factor: 29.690
Authors: Omar Saeed; Sabarivinoth Rangasamy; Ibrahim Selevany; Shivank Madan; Jeremy Fertel; Ruth Eisenberg; Mohammad Aljoudi; Snehal R Patel; Julia Shin; Daniel B Sims; Morayma Reyes Gil; Daniel J Goldstein; Marvin J Slepian; Henny H Billett; Ulrich P Jorde Journal: Circ Heart Fail Date: 2017-11 Impact factor: 8.790
Authors: Megan McCullough; Cesar Caraballo; Neal G Ravindra; P Elliott Miller; Catherine Mezzacappa; Andrew Levin; Jadry Gruen; Benjamin Rodwin; Samuel Reinhardt; David van Dijk; Ayyaz Ali; Tariq Ahmad; Nihar R Desai Journal: JAMA Cardiol Date: 2020-02-01 Impact factor: 14.676
Authors: Imad Hussain; Selma F Mohammed; Paul R Forfia; Gregory D Lewis; Barry A Borlaug; Dianne S Gallup; Margaret M Redfield Journal: Circ Heart Fail Date: 2016-04 Impact factor: 8.790
Authors: Andrew Xanthopoulos; Konstantinos Tryposkiadis; Filippos Triposkiadis; Kiyotaka Fukamachi; Edward G Soltesz; James B Young; Kathy Wolski; Eugene H Blackstone; Randall C Starling Journal: J Am Heart Assoc Date: 2020-07-10 Impact factor: 5.501